Sino Biopharmaceutical Limited (SBHMY)
USD 8.34
(0.0%)
USD 8.34
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 5.66 Billion CNY | -18.7% |
| 2022 | 6.69 Billion CNY | -64.53% |
| 2021 | 18.86 Billion CNY | 285.82% |
| 2020 | 4.88 Billion CNY | -15.84% |
| 2019 | 5.8 Billion CNY | 16.79% |
| 2018 | 4.97 Billion CNY | 19.14% |
| 2017 | 4.17 Billion CNY | -11.45% |
| 2016 | 4.71 Billion CNY | 76.02% |
| 2015 | 2.67 Billion CNY | 33.57% |
| 2014 | 2 Billion CNY | -8.66% |
| 2013 | 2.19 Billion CNY | 51.73% |
| 2012 | 1.44 Billion CNY | 77.52% |
| 2011 | 815.03 Million CNY | -12.64% |
| 2010 | 932.96 Million CNY | 32.24% |
| 2009 | 705.52 Million CNY | 31.49% |
| 2008 | 536.57 Million CNY | 43.76% |
| 2007 | 373.23 Million CNY | 56.51% |
| 2006 | 238.47 Million CNY | 49.78% |
| 2005 | 159.21 Million CNY | -43.78% |
| 2004 | 283.21 Million CNY | 58.61% |
| 2003 | 178.56 Million CNY | 23.07% |
| 2002 | 145.08 Million CNY | 14.34% |
| 2001 | 126.88 Million CNY | 35.71% |
| 2000 | 93.49 Million CNY | 34.84% |
| 1999 | 69.34 Million CNY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 501.03 Million USD | 0.0% |
| 2023 Q1 | 1.56 Billion USD | 271.22% |
| 2023 FY | 5.43 Billion CNY | -18.7% |
| 2023 Q3 | - USD | -100.0% |
| 2023 Q4 | 349.38 Million USD | 0.0% |
| 2023 Q2 | 467.22 Million USD | -70.1% |
| 2022 Q4 | 420.95 Million USD | -69.04% |
| 2022 Q1 | 1.58 Billion CNY | 96.2% |
| 2022 Q2 | 1.58 Billion CNY | 0.0% |
| 2022 FY | 6.69 Billion CNY | -64.53% |
| 2022 Q3 | 1.35 Billion USD | -13.99% |
| 2021 Q2 | 1.77 Billion CNY | 43.18% |
| 2021 Q4 | 805.67 Million CNY | 0.0% |
| 2021 Q3 | 805.67 Million CNY | -54.71% |
| 2021 FY | 18.86 Billion CNY | 285.82% |
| 2021 Q1 | 1.24 Billion CNY | 35.87% |
| 2020 Q3 | 1.24 Billion CNY | -18.45% |
| 2020 FY | 4.88 Billion CNY | -15.84% |
| 2020 Q1 | 1.19 Billion CNY | -2.17% |
| 2020 Q2 | 1.53 Billion CNY | 28.08% |
| 2020 Q4 | 914.5 Million CNY | -26.74% |
| 2019 Q1 | 1.25 Billion CNY | 90.19% |
| 2019 FY | 5.8 Billion CNY | 16.79% |
| 2019 Q4 | 1.22 Billion CNY | -35.15% |
| 2019 Q3 | 1.88 Billion CNY | 29.66% |
| 2019 Q2 | 1.45 Billion CNY | 16.17% |
| 2018 FY | 4.97 Billion CNY | 19.14% |
| 2018 Q1 | 1.03 Billion CNY | -18.09% |
| 2018 Q2 | 1.31 Billion CNY | 27.41% |
| 2018 Q3 | 1.96 Billion CNY | 48.68% |
| 2018 Q4 | 657.48 Million CNY | -66.48% |
| 2017 Q4 | 1.26 Billion CNY | -1.71% |
| 2017 Q3 | 1.28 Billion CNY | -3.61% |
| 2017 Q2 | 1.33 Billion CNY | -3.33% |
| 2017 Q1 | 1.38 Billion CNY | 20.25% |
| 2017 FY | 4.17 Billion CNY | -11.45% |
| 2016 Q3 | 1.37 Billion CNY | -18.09% |
| 2016 Q1 | 521.9 Million CNY | -32.03% |
| 2016 Q4 | 1.14 Billion CNY | -16.29% |
| 2016 FY | 4.71 Billion CNY | 76.02% |
| 2016 Q2 | 1.67 Billion CNY | 220.72% |
| 2015 Q2 | 549.84 Million CNY | 25.83% |
| 2015 FY | 2.67 Billion CNY | 33.57% |
| 2015 Q1 | 436.96 Million CNY | -18.72% |
| 2015 Q4 | 767.8 Million CNY | -16.88% |
| 2015 Q3 | 923.69 Million CNY | 67.99% |
| 2014 Q4 | 537.62 Million CNY | -27.96% |
| 2014 Q2 | 420.52 Million CNY | 16.58% |
| 2014 Q1 | 360.71 Million CNY | -68.79% |
| 2014 FY | 2 Billion CNY | -8.66% |
| 2014 Q3 | 746.25 Million CNY | 77.46% |
| 2013 Q1 | 283.62 Million CNY | -29.8% |
| 2013 Q2 | 279.78 Million CNY | -1.35% |
| 2013 Q3 | 476.1 Million CNY | 70.17% |
| 2013 Q4 | 1.15 Billion CNY | 142.74% |
| 2013 FY | 2.19 Billion CNY | 51.73% |
| 2012 Q1 | 241.99 Million CNY | -5.22% |
| 2012 Q4 | 404.03 Million CNY | 136.24% |
| 2012 Q3 | 171.02 Million CNY | -72.84% |
| 2012 Q2 | 629.77 Million CNY | 160.25% |
| 2012 FY | 1.44 Billion CNY | 77.52% |
| 2011 Q2 | 188.09 Million CNY | -2.26% |
| 2011 Q1 | 192.44 Million CNY | 0.0% |
| 2011 FY | 815.03 Million CNY | -12.64% |
| 2011 Q3 | 182.18 Million CNY | -3.14% |
| 2011 Q4 | 255.32 Million CNY | 40.15% |
| 2010 Q2 | 175.37 Million CNY | 1.95% |
| 2010 Q1 | 172.02 Million CNY | 0.0% |
| 2010 FY | 932.96 Million CNY | 32.24% |
| 2009 FY | 705.52 Million CNY | 31.49% |
| 2008 FY | 536.57 Million CNY | 43.76% |
| 2007 FY | 373.23 Million CNY | 56.51% |
| 2006 FY | 238.47 Million CNY | 49.78% |
| 2005 FY | 159.21 Million CNY | -43.78% |
| 2004 FY | 283.21 Million CNY | 58.61% |
| 2003 FY | 178.56 Million CNY | 23.07% |
| 2002 FY | 145.08 Million CNY | 14.34% |
| 2001 FY | 126.88 Million CNY | 35.71% |
| 2000 FY | 93.49 Million CNY | 34.84% |
| 1999 FY | 69.34 Million CNY | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 7998.307% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -115263.114% |
| SQZ Biotechnologies Company | -75.82 Million USD | 7577.585% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 31869.367% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | -6826.997% |
| Mesoblast Limited | -84.14 Million USD | 6838.064% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 369220.972% |
| Genus plc | 6.4 Million USD | -88491.859% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | -58097.617% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | 608861.086% |
| Marizyme, Inc. | -34.08 Million USD | 16733.789% |
| ContraFect Corporation | -56.88 Million USD | 10066.565% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 68002.743% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | 124583.427% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 404516.22% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | 199007.738% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | 206214.535% |
| MultiCell Technologies, Inc. | -722.81 USD | 784421870.59% |
| Accustem Sciences Inc. | -3.74 Million USD | 151441.294% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 9711.593% |
| EV Biologics, Inc. | -483.06 Thousand USD | 1173837.326% |
| Q BioMed Inc. | -3.44 Million USD | 164653.421% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | -160066.073% |
| Neon Bloom, Inc. | -389.57 Thousand USD | 1455519.822% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | 215888.07% |
| Biomind Labs Inc. | -1 Million USD | 561694.904% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | -4.87 Million USD | 116296.903% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | 85386.796% |
| Skye Bioscience, Inc. | -13.67 Million USD | 41571.342% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | 285523.556% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | 18929984.482% |
| Arch Therapeutics, Inc. | -5.04 Million USD | 112497.623% |
| IMV Inc. | -38.67 Million USD | 14761.643% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 35827.618% |
| Curative Biotechnology, Inc. | -1.93 Million USD | 293479.368% |
| GB Sciences, Inc. | -1.42 Million USD | 399244.18% |
| Alpha Cognition Inc. | -9.7 Million USD | 58518.629% |
| HST Global, Inc. | -140.9 Thousand USD | 4023944.805% |
| CSL Limited | 3.7 Billion USD | -53.157% |
| Halberd Corporation | -75.05 Thousand USD | 7554902.132% |
| Enzolytics Inc. | -2.14 Million USD | 263962.574% |
| Resverlogix Corp. | -12.74 Million USD | 44573.127% |
| Affymax, Inc. | -15.04 Million USD | 37783.63% |
| SYBLEU INC | -149.18 Thousand USD | 3800796.474% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | 179057.975% |
| argenx SE | -425.04 Million USD | 1433.935% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 10314.526% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | 543191.858% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | 359099.655% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | 166617.297% |
| AVAX Technologies, Inc. | 6.69 Million USD | -84615.085% |
| Zenith Capital Corp. | -8.94 Million USD | 63500.19% |
| Genscript Biotech Corporation | -415.79 Million USD | 1463.637% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | 32546331.56% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | 231022.484% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | 3305968.0% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 10414.055% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | 195528.832% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | 576276.182% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | 304217.691% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | -1.25 Million USD | 451523.487% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 282921.26% |
| BioStem Technologies, Inc. | -7.77 Million USD | 72987.281% |
| ONE Bio Corp. | 13.68 Million USD | -41341.791% |
| Reve Technologies, Inc. | -181.48 Thousand USD | 3124258.47% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | 424672.966% |
| Wesana Health Holdings Inc. | -1.12 Million USD | 504131.359% |
| Agentix Corp. | -1.37 Million USD | 413429.995% |
| LadRx Corporation | -3.82 Million USD | 148385.397% |
| Cell Source, Inc. | -4.32 Million USD | 131184.981% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | 1364760.789% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | 825469.969% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | 825469.969% |
| NovAccess Global Inc. | -2.46 Million USD | 229951.262% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | 194310.918% |
| Itoco Inc. | -919.14 Thousand USD | 616967.833% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | 133873.6% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | 506791.6% |
| Kadimastem Ltd | -3.04 Million USD | 186593.841% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | 2166441.517% |
| CytoDyn Inc. | -18.05 Million USD | 31498.156% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | 22526436.909% |
| Mobile Lads Corp. | -554.55 Thousand USD | 1022528.816% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | 2576404.31% |
| Qrons Inc. | -643.67 Thousand USD | 880957.79% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | 1004110.639% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | -2.22 Million USD | 254368.46% |
| Rebus Holdings, Inc. | -664 Thousand USD | 853997.44% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | 312263.0% |
| International Stem Cell Corporation | -663 Thousand USD | 855285.37% |
| Bioxytran, Inc. | -3.82 Million USD | 148520.44% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | 10771146.733% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | 27875611.308% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 15734.145% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | 350525.155% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | -735.83 Thousand USD | 770636.737% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | 182352.62% |
| Neutra Corp. | -229.48 Thousand USD | 2470786.229% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 32427.265% |
| PureTech Health plc | -146.19 Million USD | 3978.193% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 26482.427% |
| IXICO plc | -1.43 Million USD | 394663.605% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 59839.532% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 4754.844% |
| CSL Limited | 3.81 Billion USD | -48.738% |
| Cellectis S.A. | -108.85 Million USD | 5308.54% |